Lonsurf (trifluridine/tipiracil) / Otsuka 
Welcome,         Profile    Billing    Logout  
 6 Diseases   125 Trials   125 Trials   2571 News 


«12...1617181920212223242526...3334»
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm
    [VIRTUAL] Sarcopenia in advanced colorectal cancer patients treated with trifluridine/tipiracil () -  Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_305;    
    CEA serum level before treatment onset seems to be a significant predictive factor for TT response, but that observation must be confirmed in further studies. Optimal drug sequence in later-line CRC chemotherapy is a significant challenge due to the small number of eligible patients and searching for valuable predictive factors requires further research.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm, Stivarga (regorafenib) / Bayer
    Clinical, Journal:  Transitioning from second-line to third-line therapy in metastatic colorectal cancer. (Pubmed Central) -  Jun 1, 2021   
    Clinicians now commonly adjust the dose of regorafenib. A delay in the initiation of these third-line agents can allow the patient's performance status to decrease, thus diminishing the opportunity for a successful outcome.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Cometriq (cabozantinib capsule) / Exelixis, Cabometyx (cabozantinib tablet) / Exelixis
    Trial initiation date, Metastases:  Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy (clinicaltrials.gov) -  May 27, 2021   
    P1,  N=12, Not yet recruiting, 
    A delay in the initiation of these third-line agents can allow the patient's performance status to decrease, thus diminishing the opportunity for a successful outcome. Initiation date: Apr 2021 --> Jul 2021
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Enrollment open, Trial primary completion date, Combination therapy, Metastases:  TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma (clinicaltrials.gov) -  May 26, 2021   
    P1,  N=20, Recruiting, 
    The most common grade ≥3 toxicities which necessitated supportive therapies or a dose reduction were gastrointestinal and infection. Active, not recruiting --> Recruiting | Trial primary completion date: May 2021 --> Mar 2022
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Enrollment open, Metastases:  TIBET: TAS102 in Patients with ER-positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) -  May 20, 2021   
    P2,  N=50, Recruiting, 
    Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Jun 2022 Not yet recruiting --> Recruiting
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Avastin (bevacizumab) / Roche
    Review, Journal:  Oral drugs in the treatment of metastatic colorectal cancer. (Pubmed Central) -  May 20, 2021   
    Oral fluoropyrimidines include prodrugs capecitabine, tegafur, eniluracil/5-fluorouracil, tegafur/uracil, tegafur/gimeracil/oteracil and trifluridine/tipiracil (FTD/TPI)...Oral fluoropyrimidines such as capecitabine, as monotherapy or in combination with oxaliplatin, irinotecan or bevacizumab, are as effective as intravenous 5-fluorouracil (5-FU) in first-line treatment of mCRC...Regorafenib is an oral multikinase inhibitor used in patients in whom several previous lines of therapy have failed. Frequent AEs associated with oral drugs used in the treatment of CRC include hand-foot syndrome and gastrointestinal and haematological toxicities.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal:  Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). (Pubmed Central) -  May 12, 2021   
    (3) For patients with symptoms related to metastases or with a planned metastasis ablation, a doublet chemotherapy combined with bevacizumab or anti-EGFR antibody in the context of a RAS wild type tumor is recommended as first-line. Preliminary data suggest that regorafenib may be used, in its registered indication, in patients under 80 with a performance status of 0 and no autonomy alterations and that trifluridine-tipiracil may be used with a tight supervising of hematological function.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion, Enrollment change, Trial completion date, Metastases:  TAS-OX for Refractory Metastatic Colon Cancer (clinicaltrials.gov) -  May 12, 2021   
    P1/2,  N=43, Completed, 
    Preliminary data suggest that regorafenib may be used, in its registered indication, in patients under 80 with a performance status of 0 and no autonomy alterations and that trifluridine-tipiracil may be used with a tight supervising of hematological function. Active, not recruiting --> Completed | N=68 --> 43 | Trial completion date: Dec 2021 --> Jun 2020
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Retrospective data, Journal:  Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. (Pubmed Central) -  May 11, 2021   
    In the RAS WT population, the anti-EGFR drug showed superiority with respect to TAS-102 and regorafenib. These results should be viewed as only exploratory, and further prospective studies are warranted to validate these data.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs (clinicaltrials.gov) -  May 11, 2021   
    P1,  N=33, Recruiting, 
    No abstract available Trial completion date: Aug 2021 --> Aug 2024 | Trial primary completion date: Aug 2021 --> Aug 2023
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Cometriq (cabozantinib capsule) / Exelixis, Cabometyx (cabozantinib tablet) / Exelixis
    New P1 trial, Metastases:  Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy (clinicaltrials.gov) -  May 2, 2021   
    P1,  N=12, Not yet recruiting, 
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm
    [VIRTUAL] Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ROS study. () -  Apr 29, 2021 - Abstract #ASCO2021ASCO_4121;    
    Methods to accelerate PDT culture and drug testing are being pursued to increase the feasibility of a planned prospective study of PDT sensitivity informing patient management. This study supports the real-life efficacy and safety of trifluridine/tipiracil for refractory mCRC and identifies tumour burden, liver metastasis, alkaline phosphatase, dose reductions, and neutrophil/lymphocyte ratio as survival markers.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Trial suspension, Trial primary completion date, Combination therapy, Metastases:  Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer (clinicaltrials.gov) -  Apr 29, 2021   
    P2,  N=28, Suspended, 
    Thus, the combination of FTD/TPI and a CHK1 inhibitor exhibits effective antitumor effects, suggesting a novel therapeutic strategy for ESCC. Trial completion date: May 2021 --> May 2022 | Recruiting --> Suspended | Trial primary completion date: May 2021 --> May 2022
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial () -  Apr 26, 2021 - Abstract #ESMOGI2021ESMO_GI_80;    
    Background We conducted a phase II trial (WJOG8916G) to evaluate the efficacy and safety of the combination of trifluridine/tipiracil and cetuximab rechallenge in patients (pts) with metastatic colorectal cancer (mCRC) refractory to anti-epidermal growth factor receptor (EGFR) antibodies...Methods Major eligibility criteria were the following: histologically proven unresectable mCRC; RAS (KRAS and NRAS) exon 2,3,4 wild-type in archived tumor tissues; refractory or intolerance to fluoropyrimidines, oxaliplatin, irinotecan, and anti-angiogenic agents; refractory to anti-EGFR antibodies; and ECOG PS 0 1...Conclusions RAS, BRAF, and PIK3CA muts in ctDNA were associated with worse clinical efficacy outcomes in mCRC patients receiving anti-EGFR antibody rechallenge plus trifluridine/tipiracil. A comprehensive genomic test using ctDNA immediately before anti-EGFR antibodies rechallenge might help determine its indication.